Clinical Trial Update: A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating dutasteride 0.5 mg daily for six months in men with androgenetic alopecia has completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• DUTASTERIDE (Dutasteride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alopecia | Phase 3 | Status: COMPLETED | Results posted: 2009-04-22